Jemiet: Planning to purchase the controlling stake of Stonyheart through a cash transaction may constitute a significant asset restructuring.

Jemtech announced that the company is planning to purchase a controlling stake in Stentforce Technology Co., Ltd. in cash, the transaction price and acquisition ratio are subject to further demonstration and negotiation. After this transaction is completed, Stentforce Technology will become a subsidiary of the company. According to preliminary calculations, this transaction may constitute a major asset restructuring. The transaction is planned to be carried out in cash, without involving the issuance of shares by the company, and does not constitute a related party transaction, nor will it result in a change in the control of the listed company.